| Author/Editor | Kos, Mitja; Obradović, Marko; Mrhar, Aleš; Zucchiati-Godina, Julijana | |
| Title | Vstop novejših onkoloških zdravil v slovenski zdravstveni sistem ter njihova dostopnost bolnikom | |
| Translated title | Admission od new oncological drugs to the Slovenian health care system and their accessibility to the patients | |
| Type | članek | |
| Source | Zdrav Vestn | |
| Vol. and No. | Letnik 76, št. 9 | |
| Publication year | 2007 | |
| Volume | str. 529-38 | |
| Language | slo | |
| Abstract | The aim of the present study is to analyze the admission of anticancer drugs to the Slovenian health care system, and to evaluate patients' accessibility to these medications. Admission and accessibility to anticancer drugs was evaluated by analysing: differences in registration time among USA, selected member states of EU, and Slovenia; time from the registration to the first use in Slovenia; differences between the first use in Slovenia and the first use in selected member states of EU and by analysing the market of oncology drugs. The study included drugs of the ATCgroups such as Antitumor medications (cytostatics) (ATC = LO1) and Endocrine treatment (ATC = L02) that were used in Slovenia for the first time between 1999 to 2005. Registration data for Slovenia and EU was obtained from the registration documention of selected drugs at the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia, and the European Agency for the Evaluation of Medicinal Products (EMEA). Registration data for USA was obtained from the registration documention of selected drugs at the Food and Drug Administration (FDA). The information upon the first use of drugs in Slovenia was acquired from the PharMIS system, and the information upon the first use of drugs in selected member states of EU was obtained from the study on patients' access to oncology drugs by Nils Wilking and Bengt Jonsson, performed from 2005. Data for the market analysis of oncology drugs was obtained from the PharMIS system. (Abstract truncated at 2000 characters) | |
| Descriptors | NEOPLASMS DRUG COSTS INSURANCE, HEALTH LEGISLATION, DRUG |